8,437 Shares in Tarsus Pharmaceuticals, Inc. $TARS Bought by Fox Run Management L.L.C.

Fox Run Management L.L.C. purchased a new stake in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 8,437 shares of the company’s stock, valued at approximately $501,000.

A number of other institutional investors also recently bought and sold shares of the business. Osaic Holdings Inc. increased its holdings in shares of Tarsus Pharmaceuticals by 779.1% in the 2nd quarter. Osaic Holdings Inc. now owns 2,778 shares of the company’s stock valued at $113,000 after acquiring an additional 2,462 shares during the last quarter. Tower Research Capital LLC TRC boosted its holdings in Tarsus Pharmaceuticals by 220.3% in the second quarter. Tower Research Capital LLC TRC now owns 4,045 shares of the company’s stock valued at $164,000 after purchasing an additional 2,782 shares in the last quarter. West Wealth Group LLC purchased a new position in Tarsus Pharmaceuticals in the third quarter valued at approximately $202,000. Valeo Financial Advisors LLC acquired a new stake in Tarsus Pharmaceuticals during the third quarter worth approximately $209,000. Finally, XTX Topco Ltd purchased a new stake in shares of Tarsus Pharmaceuticals during the 2nd quarter worth approximately $227,000. 90.01% of the stock is owned by hedge funds and other institutional investors.

Key Stories Impacting Tarsus Pharmaceuticals

Here are the key news stories impacting Tarsus Pharmaceuticals this week:

• Positive Sentiment: Guggenheim set a new $90.00 price target for TARS, signaling confidence in long-term upside if the company executes on growth drivers. Guggenheim Price Target
• Positive Sentiment: Oppenheimer issued a favorable forecast for Tarsus’ stock, which may provide support if sentiment shifts back toward growth expectations. Oppenheimer Forecast
• Positive Sentiment: Tarsus announced management will participate in upcoming investor conferences — an opportunity to update investors on commercialization progress and future guidance. Investor Conferences Release
• Neutral Sentiment: Analysis pieces are debating whether the market has rerated TARS too cautiously after adoption headlines for XDEMVY, offering a counterpoint to the negative analyst actions but not delivering hard new catalysts. Yahoo Analysis
• Negative Sentiment: HC Wainwright sharply reduced near-term and multi-year EPS forecasts (Q1–Q4 2026 and FY2026–FY2029), cutting assumptions for revenue/earnings ramp — this is the primary downward pressure on the shares today. HC Wainwright Estimates Summary
• Negative Sentiment: Zacks Research downgraded TARS from “strong-buy” to “hold,” which can trigger selling from momentum/quant funds and heighten near-term caution among retail investors. Zacks Downgrade

Analyst Ratings Changes

A number of research firms recently commented on TARS. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Tarsus Pharmaceuticals in a research report on Thursday, January 22nd. Zacks Research downgraded shares of Tarsus Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Wednesday. The Goldman Sachs Group reaffirmed a “neutral” rating and set a $68.00 price objective on shares of Tarsus Pharmaceuticals in a report on Thursday, February 5th. Mizuho initiated coverage on Tarsus Pharmaceuticals in a report on Thursday, November 20th. They issued an “outperform” rating and a $100.00 target price for the company. Finally, Guggenheim upped their target price on Tarsus Pharmaceuticals from $87.00 to $90.00 and gave the company a “buy” rating in a research report on Wednesday. One equities research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $87.00.

Tarsus Pharmaceuticals Trading Down 0.5%

Shares of TARS stock opened at $75.52 on Friday. The company has a market capitalization of $3.21 billion, a P/E ratio of -46.62 and a beta of 0.57. The company has a current ratio of 3.85, a quick ratio of 4.25 and a debt-to-equity ratio of 0.21. The business’s 50 day moving average is $72.00 and its two-hundred day moving average is $68.73. Tarsus Pharmaceuticals, Inc. has a twelve month low of $38.51 and a twelve month high of $85.25.

Tarsus Pharmaceuticals (NASDAQ:TARS) last released its quarterly earnings results on Monday, February 23rd. The company reported ($0.20) EPS for the quarter, missing the consensus estimate of ($0.19) by ($0.01). Tarsus Pharmaceuticals had a negative return on equity of 19.63% and a negative net margin of 14.72%.The company had revenue of $151.67 million for the quarter, compared to analysts’ expectations of $144.56 million. Equities analysts forecast that Tarsus Pharmaceuticals, Inc. will post -3.17 EPS for the current year.

Insider Buying and Selling at Tarsus Pharmaceuticals

In other Tarsus Pharmaceuticals news, insider Dianne C. Whitfield sold 7,397 shares of the business’s stock in a transaction that occurred on Tuesday, December 16th. The stock was sold at an average price of $80.10, for a total transaction of $592,499.70. Following the transaction, the insider owned 38,958 shares in the company, valued at approximately $3,120,535.80. The trade was a 15.96% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CEO Bobak R. Azamian sold 6,000 shares of the stock in a transaction that occurred on Wednesday, December 24th. The stock was sold at an average price of $82.51, for a total value of $495,060.00. Following the transaction, the chief executive officer directly owned 857,991 shares of the company’s stock, valued at approximately $70,792,837.41. This trade represents a 0.69% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. 8.97% of the stock is currently owned by company insiders.

Tarsus Pharmaceuticals Company Profile

Tarsus Pharmaceuticals, Inc is a clinical‐stage biopharmaceutical company focused on developing novel therapies for diseases of the eye and ocular surface. The company’s research platform centers on neuro‐effector modulation to address underlying disease mechanisms rather than solely treating symptoms. Tarsus’s lead candidate, OC-01 (varenicline solution), is an intranasal formulation in Phase 3 development for the treatment of dry eye disease, a condition affecting millions worldwide and associated with significant patient discomfort and reduced quality of life.

In addition to its dry eye program, Tarsus is advancing preclinical and early‐stage programs targeting other ophthalmic indications, including allergic conjunctivitis and retinal disorders.